表紙:統合失調症:主要27ヶ国市場の予測
市場調査レポート
商品コード
626781

統合失調症:主要27ヶ国市場の予測

Epiomic Epidemiology Series: Schizophrenia Forecast in 27 Major Markets 2018-2028

出版日: | 発行: Black Swan Analysis | ページ情報: 英文 108 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
統合失調症:主要27ヶ国市場の予測
出版日: 2019年03月28日
発行: Black Swan Analysis
ページ情報: 英文 108 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の主要27ヶ国における統合失調症の罹患状況を調査し、有病者数の推移と予測、国・年齢層・性別・疾患区分別の内訳、疾患の概要、危険因子、疾患の診断と予後、主な症状や併存症などをまとめています。

調査対象国

  • 米国
  • カナダ
  • フランス
  • ドイツ
  • イタリア
  • スぺイン
  • 英国
  • ポーランド
  • オランダ
  • ベルギー
  • ノルウェー
  • スウェーデン
  • フィンランド
  • デンマーク
  • オーストリア
  • スイス
  • アイルランド
  • ロシア
  • トルコ
  • 日本
  • 中国
  • 韓国
  • インド
  • オーストラリア
  • ブラジル
  • メキシコ
  • アルゼンチン

当レポートで取り上げられる統合失調症の主な症状と共存症

  • 感情の平板化
  • 無関心
  • 注意機能障害
  • 無感情
  • 意欲低下
  • 会話の貧困
  • 引きこもり
  • 妄想
  • 厳格
  • 認知機能障害
目次
Product Code: SCHZ0023019

Schizophrenia is a mental illness characterised by psychosis, apathy and withdrawal, as well as cognitive impairment. It usually develops between late adolescence and young adult age, and although no significant differences in the prevalence of schizophrenia have been observed between men and women overall, there are differences in age at onset and tendency to present certain symptoms. Schizophrenia constitutes a significant burden to social and professional life, with more severe forms also causing basic self-care problems. With its life-long duration, it is one of the leading causes of long-term disability worldwide.

This report provides the current prevalent population for Schizophrenia across 27 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, Schizophrenia patients grouped by symptoms and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of Schizophrenia include:

  • Affective flattening
  • Apathy
  • Attentional impairment
  • Emotional withdrawal
  • Poor motivation
  • Poverty of speech
  • Social withdrawal
  • Delusions
  • Hallucinations
  • Cognitive Impairment

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy:

  • Ability to quantify patient populations in global Schizophrenia market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of Schizophrenia and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Identification of Schizophrenia patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of Schizophrenia patients.

Country Coverage